ANI Pharmaceuticals (NASDAQ:ANIP) announced results from the U.S. open-label, single-arm Phase 4 SYNCHRONICITY study evaluating fluocinolone acetonide intravitreal implant 0.18 mg in patients with chronic non-infectious inflammation affecting the back of the eye.
ANI Pharmaceuticals (NASDAQ:ANIP) announced on April 8, 2026, that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Isosorbide Mononitrate Tablets USP, 10 mg and 20 mg.
ANI Pharmaceuticals (NASDAQ:ANIP) announced today the U.S. Food and Drug Administration (FDA) approval and commercial launch of Pimozide Tablets in 1 mg and 2 mg strengths.
ANI Pharmaceuticals (NASDAQ:ANIP) reported positive six-month topline results from the Phase 4 SYNCHRONICITY trial evaluating fluocinolone acetonide intravitreal implant 0.18 mg in 108 patients with chronic non-infectious uveitis affecting the posterior segment.
ANI Pharmaceuticals (NASDAQ:ANIP) posted record fourth-quarter net revenue of $247.1 million on Friday, a 29.6% increase over the same period last year.
ANI Pharmaceuticals (NASDAQ:ANIP) reported record Q2 2026 net revenue of $266.0 million, up 25.9%, while GAAP net income reached $24.7 million.
